Temperature-dependent potential for the molecular dynamics of the superionic conductor ß-PbF2.

Molecular dynamic (MD) calculations were performed to investigate the thermodynamic and structural properties of lead fluoride (PbF2) by using a proposed inter-ionic temperature-dependent potential. This potential allows calculating with high precision the linear thermal expansivity and the lattice parameter as a temperature function. In addition, the potential can be represented as a sum of two contributions, a temperature-independent potential added to another temperature-dependent potential, considered last as a correction justified by the one-dimensional Newtonian quantum equation. Two fitting regions were considered, the first region from 300 to 700 K and the other one from 700 to 900 K. These regions arise naturally due to the smooth and continuous transition that PbF2 undergoes until it reaches the superionic state and, allows us to model with high precision the anomaly in the dependence of the lattice parameter with the temperature of this material, a feature that until now under the molecular dynamic method has not been studied. These results are all in good agreement with the experimental measurements.

DHA bioaccessibility in infant formulas and preschool children milks.

Docosahexaenoic acid (DHA, 22:6n-3) is an essential long chain polyunsaturated fatty acid associated with the development of the nervous system that has to be consumed by infants through breast milk or complementary food sources and which consumption is also usually inadequate in preschoolers. In this work, the in vitro bioaccessibility of DHA from two commercial infant formulas (8.9 and 9.1%) and two preschool children milks (6.9 and 7.2%), with similar DHA contents but formulated with different ingredients, was not improved by the presence of egg phospholipids in the product formulation. In addition, the importance of the choice of an age-appropriate in vitro digestion method was demonstrated by comparing the DHA bioaccessibility from the infant formulas by the Infogest 2.0 standardized method and a simulated digestion method specific for infants.

Hábitos de prescripción para el abordaje del dolor neuropático en España: resultados de la encuesta del grupo de trabajo de dolor neuropático de la Sociedad Española del Dolor / Prescribing habits for neuropathic pain management in Spain: results of the survey of the neuropathic pain working group of the Spanish Pain Society

Objetivos: Hace más de diez años que salieron al mercado los últimos fármacos con indicación en las guías internacionales de dolor neuropático (DN). Estas recomiendan iniciar con monoterapia y sitúan el tratamiento combinado en el segundo escalón. Un considerable número de pacientes no alcanza un suficiente alivio del dolor o mejora de su calidad de vida con los fármacos disponibles. Bajo esta perspectiva, el Grupo de Trabajo (GT) de DN de la Sociedad Española del Dolor (SED) diseñó una encuesta para el abordaje del DN mediante fármacos, técnicas intervencionistas y tratamientos fuera de indicación en nuestro medio. En este artículo se analiza solo la parte de tratamientos farmacológicos. Material y métodos: Estudio descriptivo mediante un cuestionario autoadministrado difundido por correo electrónico a los socios de la SED en dos oleadas durante 2019. Al inicio del cuestionario se realizaba una pregunta de selección sobre si utilizaban o no tratamientos fuera de ficha técnica o fuera de indicación. Solo los que respondieron afirmativamente procedieron a todo el conjunto de preguntas. Este se dividió en los siguientes bloques: antiepilépticos, antidepresivos, antipsicóticos, anestésicos, anti-nmda, cannabinoides, naltrexona, tratamientos tópicos, toxina botulínica, polifarmacia y tratamientos fuera de ficha. Dentro de la sección de tratamientos tópicos se incluyó la toxina botulínica. Resultados: La tasa de respuesta fue del 13,82 %, siendo del 10,05 % una vez descartadas las no válidas. El 21 % comienzan el tratamiento del DN con polifarmacia y un 43 % lo hace cuando no responden a una primera línea. El 40 % de los encuestados opinan que no hay evidencia suficiente para el uso de polifarmacia. El 70 % de los participantes trataban hasta un 30 % de sus pacientes con DN con fármacos fuera de indicación. El 23,3 % utilizaban medicamentos fuera de ficha técnica entre el 40 % y el 60 % de los pacientes con DN y un 6,6 % lo hacía en un 70-90 %...(AU)

Objectives: Latest drugs with an indication for neuropathic pain (NP) in the international guidelines came onto the market more than ten years ago. They recommend starting with monotherapy and place the combined treatment in the second step. A considerable number of patients do not achieve sufficient pain relief or improvement in their quality of life with the available drugs. From this perspective, the NP Working Group (WG) of the Spanish Pain Society (SED) designed a survey to address how NP drugs, off-label treatments and interventional techniques are being used in our setting. In this article we will only discuss the pharmacological treatment options.Material and methods: Descriptive study using a self-administered questionnaire distributed by email to SED members in two waves during 2019. At the beginning of the questionnaire, a selection question was asked whether or not they used non-technical or off-label treatments. Only those who answered affirmatively proceeded to the entire set of questions. It was divided into the following blocks: antiepileptics, antidepressants, antipsychotics, anesthetics, anti-nmda, cannabinoids, naltrexone, topical treatments, botulinum toxin, polypharmacy and off-label treatments. Botulinum toxin was included in the topical treatments section. Results: The response rate was 13.82 %, being 10.05 % once the invalid ones had been ruled out. 21 % begin the treatment of NP directly on polypharmacy and 43 % do so when they do not respond to a first line. 40 % of those surveyed think that there is insufficient evidence for the use of polypharmacy. 70 % of the participants treated up to 30 % of their NP patients with off-label drugs. 23.3 % used off-label me­dications in between 40 % and 60 % of patients with NP and 6.6 % did so in 70-90 % of patients...(AU)

Hemotórax masivo derecho por rotura espontánea idiopática de una arteria frénica tras cirugía cardiaca / Massive right hemothorax due to idiopathic spontaneous rupture of a phrenic artery following cardiac surgery

Presentamos el caso de un hombre de 35 años que en el postoperatorio de cirugía cardiaca presenta un hemotórax masivo y shock hipovolémico por rotura espontánea de una arteria frénica. Un rápido diagnóstico y una inmediata intervención son cruciales para el manejo del paciente

We report a case of a 35-years-old man who presented a massive haemothorax and hypovolemic shock following cardiac surgery, from spontaneous rupture of a phrenic artery. A quick diagnosis and immediate intervention is crucial to manage the patient

Massive right hemothorax due to idiopathic spontaneous rupture of a phrenic artery following cardiac surgery. / Hemotórax masivo derecho por rotura espontánea idiopática de una arteria frénica tras cirugía cardiaca.

We report a case of a 35-years-old man who presented a massive haemothorax and hypovolemic shock following cardiac surgery, from spontaneous rupture of a phrenic artery. A quick diagnosis and immediate intervention is crucial to manage the patient.

Crystallinity and lowering band gap induced visible light photocatalytic activity of TiO2/CS (Chitosan) nanocomposites.

The inhibition of electrons-holes recombination and enhancement of visible light photocatalytic activity were accomplished by the synthesized TiO2/CS nanocomposites system. In this present work, the different weight ratio of TiO2 and chitosan (75:25, 50:50 and 25:75) nanocomposites were synthesized via two-step method. After that, the existing functional groups, size and structure of the nanocomposites system were characterized via FT-IR, TEM and XRD measurements. The band gap of the prepared materials and its excitation and emission spectra were elevated through UV-vis and PL analyses. Moreover, the MO and MB degradation capability of the synthesized TiO2/CS nanocomposites was optimized, and the outcomes are described in detail.

The shell effect on the room temperature photoluminescence from ZnO/MgO core/shell nanowires: exciton-phonon coupling and strain.

The room temperature photoluminescence from ZnO/MgO core/shell nanowires (NWs) grown by a simple two-step vapor transport method was studied for various MgO shell widths (w). Two distinct effects induced by the MgO shell were clearly identified. The first one, related to the ZnO/MgO interface formation, is evidenced by strong enhancements of the zero-phonon and first phonon replica of the excitonic emission, which are accompanied by a total suppression of its second phonon replica. This effect can be explained by the reduction of the band bending within the ZnO NW core that follows the removal of atmospheric adsorbates and associated surface traps during the MgO growth process on one hand, and a reduced exciton-phonon coupling as a result of the mechanical stabilization of the outermost ZnO NW monolayers by the MgO shell on the other hand. The second effect is the gradual increase of the excitonic emission and decrease in the defect related emission by up to two and one orders of magnitude, respectively, when w is increased in the ∼3-17 nm range. Uniaxial strain build-up within the ZnO NW core with increasing w, as detected by x-ray diffraction measurements, and photocarrier tunneling escape from the ZnO core through the MgO shell enabled by defect-states are proposed as possible mechanisms involved in this effect. These findings are expected to be of key significance for the efficient design and fabrication of ZnO/MgO NW heterostructures and devices.

Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España / Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain

OBJETIVO: Realizar un análisis coste-efectividad y coste-utilidad de ingenol mebutato en el tratamiento de la queratosis actínica en España. MÉTODOS: Se realizó la adaptación de un modelo de Markov que simuló una cohorte de pacientes (73 años de media) con queratosis actínica en un horizonte temporal de 5 años. Los comparadores fueron diclofenaco 3% e imiquimod 5%. El análisis se desarrolló desde la perspectiva del Sistema Nacional de Salud, incluyendo costes directos sanitarios (PVPIVA con la deducción obligatoria, € 2015). La estimación de recursos se llevó a cabo por un panel de expertos y los costes unitarios se obtuvieron de bases de datos de costes nacionales. La tasa de descuento considerada fue del 3% anual. Se realizaron análisis de sensibilidad determinísticos y probabilísticos. RESULTADOS: Ingenol mebutato fue más eficiente frente a diclofenaco, con 0,192 aclaramientos incrementales en la cara y el cuero cabelludo y 0,129 en el tronco y las extremidades. Los costes totales fueron de 551,50€ y 622,27€ comparados con 849,11€ y 844,93€ en diclofenaco (cara y cuero cabelludo y tronco y extremidades, respectivamente). Es decir, ingenol mebutato es una alternativa de tratamiento dominante frente a diclofenaco 3%. Ingenol mebutato también mostró una mayor eficacia frente a imiquimod 5%, con 0,535 vs. 0,503 aclaramientos ganados, y unos costes totales de 551,50€ vs. 527,89€, siendo la relación coste-efectividad incremental resultante de 728,64€/aclaramiento adicional. CONCLUSIONES: Ingenol mebutato resultó ser una estrategia dominante vs. diclofenaco, y eficiente, es decir, presentó mayor efectividad y mayores costes (relación coste-utilidad incremental inferior a 30.000€/AVAC) vs. Imiquimod

OBJECTIVE: To perform a cost-effectiveness and cost-utility analysis of ingenol mebutate in the treatment of actinic keratosis in Spain. METHODS: We used an adapted Markov model to simulate outcomes in a cohort of patients (mean age, 73 years) with actinic keratosis over a 5-year period. The comparators were diclofenac 3% and imiquimod 5%. The analysis was performed from the perspective of the Spanish National Health System based on direct costs (2015 retail price plus value added tax less the mandatory discount). A panel of experts estimated resources, taking unit costs from national databases. An annual discount rate of 3% was applied. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The effectiveness of ingenol mebutate-with 0.192 and 0.129 more clearances gained in treatments for face and scalp lesions and trunk and extremity lesions, respectively-was superior to diclofenac's. The total costs of treatment with ingenol mebutate were lower at € 551.50 (face and scalp) and € 622.27 (trunk and extremities) than the respective costs with diclofenac (€ 849.11 and € 844.93). The incremental cost-effectiveness and cost-utility ratios showed that ingenol mebutate was a dominant strategy vs diclofenac. Ingenol mebutate also proved to be more effective than imiquimod, based on 0.535 and 0.503 additional clearances, and total costs of € 551.50 and € 527.89 for the two drugs, respectively. The resulting incremental cost-effectiveness ratio was € 728.64 per clearance gained with ingenol mebutate vs imiquimod. CONCLUSIONS: Ingenol mebutate was a dominant treatment option vs diclofenac and was efficient vs imiquimod (i.e., more effective at a higher cost, achieving an incremental cost-utility ratio of<€30000/quality-adjusted life-years)

Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. / Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España.

OBJECTIVE: To perform a cost-effectiveness and cost-utility analysis of ingenol mebutate in the treatment of actinic keratosis in Spain. METHODS: We used an adapted Markov model to simulate outcomes in a cohort of patients (mean age, 73 years) with actinic keratosis over a 5-year period. The comparators were diclofenac 3% and imiquimod 5%. The analysis was performed from the perspective of the Spanish National Health System based on direct costs (2015 retail price plus value added tax less the mandatory discount). A panel of experts estimated resources, taking unit costs from national databases. An annual discount rate of 3% was applied. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The effectiveness of ingenol mebutate-with 0.192 and 0.129 more clearances gained in treatments for face and scalp lesions and trunk and extremity lesions, respectively-was superior to diclofenac's. The total costs of treatment with ingenol mebutate were lower at € 551.50 (face and scalp) and € 622.27 (trunk and extremities) than the respective costs with diclofenac (€ 849.11 and € 844.93). The incremental cost-effectiveness and cost-utility ratios showed that ingenol mebutate was a dominant strategy vs diclofenac. Ingenol mebutate also proved to be more effective than imiquimod, based on 0.535 and 0.503 additional clearances, and total costs of € 551.50 and € 527.89 for the two drugs, respectively. The resulting incremental cost-effectiveness ratio was € 728.64 per clearance gained with ingenol mebutate vs imiquimod. CONCLUSIONS: Ingenol mebutate was a dominant treatment option vs diclofenac and was efficient vs imiquimod (i.e., more effective at a higher cost, achieving an incremental cost-utility ratio of<€30000/quality-adjusted life-years).

Dolor en la articulación sacroilíaca: estudio prospectivo, aleatorizado, experimental y comparativo de la radiofrecuencia térmica con el bloqueo de la articulación sacroilíaca / Sacroiliac joint pain: Prospective, randomised, experimental and comparative study of thermal radiofrequency with sacroiliac joint block

Objetivo. Comparar el bloqueo con la radiofrecuencia térmica bipolar para el dolor de la articulación sacroilíaca. Método. Estudio prospectivo, aleatorizado y experimental en 60 pacientes, seleccionados en 9 meses en 2 centros, con dolor intenso (escala visual analógica [EVA] > 6) de > 3 meses de duración. Fueron divididos en 3 grupos (n = 20). Grupo A: pacientes a los que se les realizaron 2 bloqueos intraarticulares, con control ecográfico en 7 días. Grupo B: radiofrecuencia bipolar «palisade» utilizando 6 agujas perpendiculares a la zona dorsal del sacro, a una distancia de 1 cm, para producir lesiones contiguas entre los forámenes S1-S2-S3 y la línea articular. Grupo C: radiofrecuencia bipolar «palisade» modificada (distancia entre agujas > 1 cm). Los pacientes fueron evaluados al mes, a los 3 y a los 12 meses del tratamiento. Se valoraron los datos demográficos (en la visita basal), la eficacia analgésica y los efectos secundarios (en el resto). Resultados. Al mes, la reducción del dolor en los 3 grupos fue > 50% (p ≤ 0,001). A los 3 y 12 meses el grupo A no refirió disminución significativa del dolor. El grupo B, a los 3 meses, alivio cercano al 50% (p = 0,03), y < 25% (23,8) a los 12 meses (p = 0,01). En el grupo C, alivio próximo al 50% a los 3 y 12 meses (p < 0,001) respecto al basal. Todos los pacientes finalizaron el estudio. Conclusiones. La radiofrecuencia bipolar «palisade», especialmente aumentando la distancia entre las agujas, ha sido eficaz, a más largo plazo, que el bloqueo con anestésicos y corticoides en el alivio del dolor de la articulación sacroilíaca (AU)

Objective. To compare the analgesic effects between the blockade and bipolar thermal radiofrequency in the treatment of sacroiliac joint pain. Method. Prospective, randomised and experimental study conducted on 60 patients selected in the two hospitals over a period of nine months, who had intense sacroiliac joint pain (Visual Analogue Scale [VAS] > 6) that lasted more than 3 months. Patients were randomised into three groups (n = 20): Group A (two intra-articular sacroiliac injections of local anaesthetic/corticosteroid guided by ultrasound in 7 days). Group B: conventional bipolar radiofrequency «palisade». Target points were the lateral branch nerves of S1, S2, and S3, distance needles 1 cm. Group C: modified bipolar radiofrequency «palisade» (needle distance > 1 cm). Patients were evaluated at one month, three months, and one year. Demographic data, VAS reduction, and side effects of the techniques were assessed. Results. One month after the treatment, pain reduction was > 50% in the three groups P < .001. Three and 12 months after the technique, the patients of the group A did not have a significant reduction in pain. At 3 months, almost 50% patients of the group B referred to improvement of the pain (P = .03), and < 25% at 12 months, and those results were statistically significant (P = .01) compared to the baseline. Group C showed an improvement of 50% at 3 and 12 months (P < .001). All patients completed the study. Conclusions. Bipolar radiofrequency «palisade», especially when the distance between the needles was increased, was more effective and lasted longer, compared to join block and steroids, in relieving pain sacroiliac joint (AU)

Sacroiliac joint pain: Prospective, randomised, experimental and comparative study of thermal radiofrequency with sacroiliac joint block.

OBJECTIVE: To compare the analgesic effects between the blockade and bipolar thermal radiofrequency in the treatment of sacroiliac joint pain. METHOD: Prospective, randomised and experimental study conducted on 60 patients selected in the two hospitals over a period of nine months, who had intense sacroiliac joint pain (Visual Analogue Scale [VAS]>6) that lasted more than 3 months. Patients were randomised into three groups (n=20): Group A (two intra-articular sacroiliac injections of local anaesthetic/corticosteroid guided by ultrasound in 7 days). Group B: conventional bipolar radiofrequency "palisade". Target points were the lateral branch nerves of S1, S2, and S3, distance needles 1cm. Group C: modified bipolar radiofrequency "palisade" (needle distance >1cm). Patients were evaluated at one month, three months, and one year. Demographic data, VAS reduction, and side effects of the techniques were assessed. RESULTS: One month after the treatment, pain reduction was >50% in the three groups P<.001. Three and 12 months after the technique, the patients of the group A did not have a significant reduction in pain. At 3 months, almost 50% patients of the group B referred to improvement of the pain (P=.03), and <25% at 12 months, and those results were statistically significant (P=.01) compared to the baseline. Group C showed an improvement of 50% at 3 and 12 months (P<.001). All patients completed the study. CONCLUSIONS: Bipolar radiofrequency "palisade", especially when the distance between the needles was increased, was more effective and lasted longer, compared to join block and steroids, in relieving pain sacroiliac joint.

ZnO/Ag/CdO nanocomposite for visible light-induced photocatalytic degradation of industrial textile effluents.

A ternary ZnO/Ag/CdO nanocomposite was synthesized using thermal decomposition method. The resulting nanocomposite was characterized by X-ray diffraction, field emission scanning electron microscopy, transmission electron microscopy, UV-Vis spectroscopy, and X-ray photoelectron spectroscopy. The ZnO/Ag/CdO nanocomposite exhibited enhanced photocatalytic activity under visible light irradiation for the degradation of methyl orange and methylene blue compared with binary ZnO/Ag and ZnO/CdO nanocomposites. The ZnO/Ag/CdO nanocomposite was also used for the degradation of the industrial textile effluent (real sample analysis) and degraded more than 90% in 210 min under visible light irradiation. The small size, high surface area and synergistic effect in the ZnO/Ag/CdO nanocomposite is responsible for high photocatalytic activity. These results also showed that the Ag nanoparticles induced visible light activity and facilitated efficient charge separation in the ZnO/Ag/CdO nanocomposite, thereby improving the photocatalytic performance.

Enhanced GABAergic tone in the ventral pallidum: memory of unpleasant experiences?

The nucleus accumbens (NAc) has emerged as an important part of the neural circuitry regulating depressive-like behaviors. Given that the NAc GABAergic medium spiny neurons project to the ventral pallidum (VP), it is reasonable to suggest that the VP may also be involved in these behaviors. Consequently, we explored the role of the VP GABAergic terminals during depressive-like behaviors in rats using the forced swim test (FST) and the sucrose preference test (SPT). Microdialysis coupled with micellar electrokinetic chromatography was used to monitor in vivo changes of GABA in the VP during the FST. GABA levels significantly increased during day-1 and day-2 during swimming, returning to the pre-swimming levels after the test. Basal concentrations of GABA on day-2 of the FST significantly increased with respect to day-1. In another set of experiments, intra-VP injections of vigabatrin (a GABA transaminase inhibitor) increased extracellular GABA and immobility behaviors in the FST while the direct GABAA receptor antagonist bicuculline reduced immobility behaviors. In the SPT, intra-VP vigabatrin injection significantly reduced preference for sucrose while bicuculline did not produce any change. At the postsynaptic side, we used semiquantitative RT-PCR to measure mRNA expression of 17 GABAA receptor subunits (α1-α6, ß1-ß3, γ2, δ, ε, θ, π, and ρ1-ρ3) in rats subjected to the FST. We found a significant reduction of α3 and γ2 subunit expression and an increase of δ subunit expression after day-2 in rats subject to the FST which might enhance tonic inhibition of the VP. Furthermore, immunoblot experiments revealed that protein expression of γ2 and δ subunits changed 6 days after FST in a way similar to mRNA expression. These results suggest that the enhanced VP-GABAergic tone might trigger a low motivational state, anhedonia and a possible memory mechanism for unpleasant experiences.

Aplicación de la proteómica a las enfermedades neurológicas / Application of the proteomic to neurological diseases

La proteómica es un conjunto de técnicas que permiten la separación e identificación de las proteínas expresadas por una célula, tejido u organismo. La técnica central de esta disciplina es la electroforesis bidimensional, que permite llevar a cabo comparaciones cualitativas y cuantitativas de los patrones proteicos entre muestras dadas. El análisis diferencial de los patrones de expresión en distintas patologías neurológicas (ictus, Alzheimer, Parkinson, esclerosis lateral amiotrófica, Hungtington, epilepsia) permite la identificación de biomarcadores de diagnóstico y/o pronóstico. La posterior validación de estos marcadores llevaría a la identificación de nuevas dianas diagnósticas y terapéuticas

Proteomic is a set of tools that allows the separation and identification of proteins expressed by a cell, tissue or organism. Two-dimensional electrophoresis is the central tool that allows qualitative and quantitative comparisons of protein patterns between samples. Differential analysis of protein expression patterns in different neurological diseases (stroke, Alzheimer, Parkinson, amyotrophic lateral sclerosis, Hungtington, epilepsy) allows the identification of diagnostic and/or prognostic biomarkers. Subsequently, validation of these markers may help to identify new diagnostic and therapeutic targets

[Application of proteomics to neurological diseases]. / Aplicación de la proteómica a las enfermedades neurológicas.

Proteomic is a set of tools that allows the separation and identification of proteins expressed by a cell, tissue or organism. Two-dimensional electrophoresis is the central tool that allows qualitative and quantitative comparisons of protein patterns between samples. Differential analysis of protein expression patterns in different neurological diseases (stroke, Alzheimer, Parkinson, amyotrophic lateral sclerosis, Hungtington, epilepsy) allows the identification of diagnostic and/or prognostic biomarkers. Subsequently, validation of these markers may help to identify new diagnostic and therapeutic targets.

[Procalcitonin for the diagnosis of neonatal sepsis of vertical transmission]. / Procalcitonina para el diagnóstico de sepsis neonatal de transmisión vertical.

OBJECTIVE: To evaluate procalcitonin (PCT) as a diagnostic marker of neonatal sepsis of vertical transmission and to compare the results of PCT with those of the most widely used laboratory tests for sepsis. PATIENTS AND METHODS: A prospective study was conducted in 136 blood samples from 69 newborn infants admitted to a neonatal department. PCT, C-reactive protein (CRP), leukocyte count, and the immature-to-total neutrophil ratio (I/T ratio) were measured. The PCT reference range of controls from 0 to 72 hours of life was constructed, and the diagnostic efficiency of the tests was calculated, with their 95 % confidence intervals (95 % CI). RESULTS: This study included 35 controls, 24 neonates with noninfectious disorders, and 10 neonates with sepsis (5 with culture-proven sepsis). PCT, CRP, and the I/T ratio discriminated septic from nonseptic patients. Their areas under the ROC curve were 0.696 (p = 0.009), 0.735 (p = 0.002), and 0.703 (p = 0.006), respectively, with no statistically significant differences. The accuracy of PCT, CRP, and leukocyte count improved after 24 hours of life with areas under the ROC curve of 0.813 (p = 0.007), 0.826 (p = 0.005), and 0.841 (p = 0.003), respectively. Overall, PCT detected vertically transmitted sepsis with a sensitivity of 68.4 % (95 % CI: 46.0 %-84.6 %), specificity of 82.4 % (95 % CI: 72.2 %-89.4 %), positive likelihood ratio of 3.89 (95 % CI: 2.18 %-6.96 %), and negative likelihood ratio of 0.38 (95 % CI: 0.19 %-0.76 %), similar to those of CRP. CONCLUSIONS: PCT may be a useful marker for the diagnosis of vertically transmitted sepsis. Studies with larger sample sizes are required to establish the accuracy of PCT.

[Procalcitonin for the diagnosis of nosocomial neonatal sepsis]. / Procalcitonina para el diagnóstico de sepsis neonatal de origen nosocomial.

BACKGROUND: Nosocomial sepsis is a major problem in neonatal units. Because the clinical signs are nonspecific, highly reliable diagnostic markers are required to guide diagnosis. The aim of this study was to evaluate the utility of procalcitonin (PCT) as a diagnostic marker for nosocomial neonatal sepsis, and to compare the results of PCT with those of the most widely used laboratory tests for sepsis. PATIENTS AND METHODS: Twenty neonates with nosocomial sepsis and 20 controls aged 4-30 days were included in a prospective study performed in a neonatal intensive care unit. PCT, C-reactive protein (CRP), leukocyte count, and the immature-to-total neutrophil ratio (I/T ratio) were measured at onset of signs of infection. The sensitivity, specificity, and likelihood ratio for a positive (LR+) and a negative (LR-) result were calculated. RESULTS: PCT, CRP, and the I/T ratio discriminated septic from nonseptic patients. Their areas under the ROC curve were 0.849, 0.880, and 0.884, respectively, with no statistically significant differences. Optimal cut-off values were: PCT > or = 0.65 ng/ml (sensitivity 85 %, specificity 80 %, LR 1 4.25, LR- 0.19), PCR > or = 5 .g/ml (sensitivity 80 %, specificity 95 %, LR 1 16, LR- 0.21), and I/T > or = 0.03 (sensitivity 90 %, specificity 75 %, LR 1 3.6, LR- 0.13). CONCLUSIONS: PCT may be a useful marker for the diagnosis of nosocomial neonatal sepsis. Studies with larger samples are required to compare the accuracy of PCT with that of other markers of sepsis.

Procalcitonina para el diagnóstico de sepsis neonatal de transmisión vertical / Procalcitonin for the diagnosis of neonatal sepsis of vertical transmission

Objetivo: Evaluar la utilidad de la procalcitonina (PCT) para el diagnóstico de sepsis neonatal de transmisión vertical y comparar sus resultados con los marcadores de sepsis más utilizados. Pacientes y métodos: Estudio prospectivo sobre 136 muestras de 69 recién nacidos ingresados en un servicio de neonatología. Se midieron la PCT, proteína C reactiva (PCR), recuento leucocitario e índice de neutrófilos inmaduros/totales (índice I/T). Se construyó el rango de normalidad de la PCT entre 0 y 72 h de vida y se calculó la eficacia diagnóstica de los marcadores de infección estudiados con sus intervalos de confianza del 95 % (IC 95 %). Resultados: Se incluyeron 35 controles, 24 neonatos con procesos no infecciosos y 10 diagnosticados de sepsis (cinco con confirmación bacteriológica). PCT, PCR e índice I/T mostraron capacidad diagnóstica, con áreas bajo la curva COR de 0,696 (p 5 0,009), 0,735 (p 5 0,002) y 0,703 (p 5 0,006), respectivamente, sin diferencias estadísticamente significativas. El rendimiento mejoró a partir de las 24 h de vida para PCT, PCR y recuento leucocitario, con áreas bajo la curva COR de 0,813 (p 5 0,007), 0,826 (p 5 0,005) y 0,841 (p 5 0,003), respectivamente. Globalmente la PCT detectó sepsis de transmisión vertical con sensibilidad del 68,4 % (IC 95 %: 46,0-84,6), especificidad 82,4 % (IC 95 %: 72,2-89,4), cociente de probabilidades del positivo 3,89 (IC 95 %: 2,18-6,96) y cociente de probabilidades del negativo 0,38 (IC 95 %: 0,19-0,76), similares a la PCR. Conclusiones: La PCT puede ser una herramienta útil para el diagnóstico de sepsis de transmisión vertical. Es necesario disponer de estudios con mayor número de pacientes

Objective: To evaluate procalcitonin (PCT) as a diagnostic marker of neonatal sepsis of vertical transmission and to compare the results of PCT with those of the most widely used laboratory tests for sepsis. Patients and Methods: A prospective study was conducted in 136 blood samples from 69 newborn infants admitted to a neonatal department. PCT, C-reactive protein (CRP), leukocyte count, and the immature-to-total neutrophil ratio (I/T ratio) were measured. The PCT reference range of controls from 0 to 72 hours of life was constructed, and the diagnostic efficiency of the tests was calculated, with their 95 % confidence intervals (95 % CI). Results: This study included 35 controls, 24 neonates with noninfectious disorders, and 10 neonates with sepsis (5 with culture-proven sepsis). PCT, CRP, and the I/T ratio discriminated septic from nonseptic patients. Their areas under the ROC curve were 0.696 (p 5 0.009), 0.735 (p 5 0.002), and 0.703 (p 5 0.006), respectively, with no statistically significant differences. The accuracy of PCT, CRP, and leukocyte count improved after 24 hours of life with areas under the ROC curve of 0.813 (p 5 0.007), 0.826 (p 5 0.005), and 0.841 (p 5 0.003), respectively. Overall, PCT detected vertically transmitted sepsis with a sensitivity of 68.4 % (95 % CI: 46.0 %-84.6 %), specificity of 82.4 % (95 % CI: 72.2 %-89.4 %), positive likelihood ratio of 3.89 (95 % CI: 2.18 %-6.96 %), and negative likelihood ratio of 0.38 (95 % CI: 0.19 %-0.76 %), similar to those of CRP. Conclusions: PCT may be a useful marker for the diagnosis of vertically transmitted sepsis. Studies with larger sample sizes are required to establish the accuracy of PCT

Procalcitonina para el diagnóstico de sepsis neonatal de origen nosocomial / Procalcitonin for the diagnosis of nosocomial neonatal sepsis

Antecedentes: La sepsis nosocomial supone una de las mayores preocupaciones en las unidades de neonatología y, dada la falta de especificidad de sus síntomas, se hacen necesarias pruebas complementarias muy fiables para orientar el diagnóstico. El objetivo de este estudio es evaluar la utilidad de la procalcitonina (PCT) para el diagnóstico de sepsis neonatal de origen nosocomial y comparar sus resultados con los marcadores de sepsis más utilizados. Pacientes y métodos: Estudio prospectivo realizado en una unidad de cuidados intensivos neonatales. Se incluyeron 20 casos de sepsis nosocomial y 20 controles de entre 4 y 30 días de vida. Se midieron la PCT, proteína C reactiva (PCR), recuento leucocitario e índice de neutrófilos inmaduros/totales (índice I/T) en el momento de la sospecha de sepsis. Se calculó la sensibilidad, especificidad, valores predictivos y cocientes de probabilidades del positivo (CPP) y del negativo (CPN) de los marcadores de infección estudiados. Resultados: PCT, PCR e índice I/T mostraron capacidad diagnóstica, con áreas bajo la curva COR de 0,849, 0,880 y 0,884, respectivamente, sin diferencias estadísticamente significativas. Los puntos de corte óptimos fueron: PCT >= 0,65 ng/ml (sensibilidad 85%; especificidad 80%; CPP 4,25; CPN 0,19), PCR >= 5 mg/ml (sensibilidad 80%; especificidad 95%; CPP 16; CPN 0,21) e índice I/T >= 0,03 (sensibilidad 90%; especificidad 75%; CPP 3,6; CPN 0,13). Conclusiones: La PCT puede ser una herramienta útil para el diagnóstico de sepsis nosocomial en neonatos, aunque es necesario disponer de estudios con mayor número de pacientes para poder comparar su rendimiento con el de otros marcadores de sepsis neonatal

Background: Nosocomial sepsis is a major problem in neonatal units. Because the clinical signs are nonspecific, highly reliable diagnostic markers are required to guide diagnosis. The aim of this study was to evaluate the utility of procalcitonin (PCT) as a diagnostic marker for nosocomial neonatal sepsis, and to compare the results of PCT with those of the most widely used laboratory tests for sepsis. Patients and Methods: Twenty neonates with nosocomial sepsis and 20 controls aged 4-30 days were included in a prospective study performed in a neonatal intensive care unit. PCT, C-reactive protein (CRP), leukocyte count, and the immature-to-total neutrophil ratio (I/T ratio) were measured at onset of signs of infection. The sensitivity, specificity, and likelihood ratio for a positive (LR1) and a negative (LR­) result were calculated. Results: PCT, CRP, and the I/T ratio discriminated septic from nonseptic patients. Their areas under the ROC curve were 0.849, 0.880, and 0.884, respectively, with no statistically significant differences. Optimal cut-off values were: PCT >= 0.65 ng/ml (sensitivity 85 %, specificity 80 %, LR 1 4.25, LR­ 0.19), PCR >= 5 mg/ml (sensitivity 80 %, specificity 95 %, LR 1 16, LR­ 0.21), and I/T >= 0.03 (sensitivity 90 %, specificity 75 %, LR 1 3.6, LR­ 0.13). Conclusions: PCT may be a useful marker for the diagnosis of nosocomial neonatal sepsis. Studies with larger samples are required to compare the accuracy of PCT with that of other markers of sepsis

Genetic variability of the marine mussel Mytilus galloprovincialis assessed using two-dimensional electrophoresis.

Two-dimensional electrophoresis (2-DE) has been used to measure the degree of genetic variability of the marine mussel Mytilus galloprovincialis. Genetic polymorphisms were detected in 33 of a total of 86 polypeptides scored among the most abundant proteins from foot samples in 38 individuals. Estimates of average heterozygosity were 0.101+/-0.018 and 0.114+/-0.021 in a natural and a cultured population, respectively, from the NW of the Iberian Peninsula. These are the highest estimates of average heterozygosity reported by 2-DE in an animal species to date. We consider that these data throw open the question of the level of genetic variability detectable by two-dimensional electrophoresis. Multilocus genotype data were used to infer haplotypic frequencies by means of the EM algorithm in order to detect linkage disequilibrium between loci coding abundant proteins. Significant associations were found in 22.7% of the 406 two-locus pairs analysed. Also, clusters of loci in which all pairwise combinations exhibit statistically significant associations were detected and physical linkage between some of these loci is postulated from the linkage disequilibrium data.